Streetbeat News

Products Services

NIO

TSLA

Nio (9866.HK) plans to launch its more affordable Firefly brand in Europe by 2025, targeting family-oriented consumers with smaller models. The move comes as Chinese EV makers seek to expand in Europe amid slowing domestic demand and a cost advantage over Western competitors. However, the EU is scrutinizing Chinese EV imports for potential competition rule breaches. Nio, facing increased losses due to a price war initiated by Tesla (TSLA.O) and higher production costs, has reduced its workforce by 10% and is exploring spin-offs and partnerships to reduce expenses. Partnerships with Geely (0175.HK) and Changan Automobile (000625.SZ) aim to develop a new battery pack and chassis architecture.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 1:39 pm

INTC

MSFT

NVDA

Microsoft Corp (NASDAQ:MSFT) is advancing in AI chipmaking with its new Maia 100 chip, which utilizes liquid cooling, a more efficient method than traditional air cooling. This shift is driven by the need to manage the heat from power-intensive AI chips, like Nvidia Corp's (NASDAQ:NVDA) H100 AI accelerator. Microsoft plans to install Maia chips and cooling hardware in data centers from 2024, with Azure expanding liquid cooling operations. Intel Corp (NASDAQ:INTC) is also exploring liquid cooling and has updated policies to support customer-created liquid cooling systems. The move towards liquid cooling is crucial for data center evolution, especially for AI demands. Equinix plans to use warm water outflow for heating at the 2024 Paris Olympics. MSFT shares saw a slight increase in premarket trading.

Portfolio Pulse from Anusuya Lahiri

December 15, 2023 | 1:37 pm

AMZN

Jeff Bezos, founder of Amazon.com, Inc. (NASDAQ:AMZN) and Blue Origin, discussed his feelings and thoughts when he left his job in New York to start Amazon during a podcast interview with Lex Fridman. Bezos acknowledged the low odds of success at the time, estimating them at 30%, and emphasized the need for a balance between realism and optimism in startups. Despite challenges, Bezos expressed gratitude for the journey with Amazon, which now has a market cap of $1.537 trillion. The company's stock has seen tremendous growth since its IPO in 1997.

Portfolio Pulse from Ananya Gairola

December 15, 2023 | 1:30 pm

TAK

Takeda Pharmaceutical Company Limited has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for HYQVIA as a maintenance therapy for patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The European Commission will review this opinion for potential marketing authorization in the EU. HYQVIA is an up to once-monthly subcutaneous treatment that can be administered at home or in-office. The CHMP's positive opinion is based on the Phase 3 ADVANCE-CIDP 1 study, which met its primary endpoint by showing a statistically significant reduction in the relapse rate of CIDP patients.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 1:23 pm

TSLA

Univision has claimed copyright on a YouTube video featuring Tesla's Gen 2 Optimus robot, which has led to a response from Elon Musk. Farzad Mesbahi, a former Tesla employee and stockholder, posted a video including the Optimus bot, and received a copyright notice from Univision. Mesbahi and others have been prevented from monetizing their content due to this claim. Tesla's Gen 2 Optimus robot has been upgraded with faster walking speed, lighter weight, and improved body control, including hands capable of delicate tasks.

Portfolio Pulse from Anan Ashraf

December 15, 2023 | 1:22 pm

EADSY

Airbus SE (OTC:EADSY) is in advanced discussions with Atos to acquire its cybersecurity division BDS, which is part of Eviden. Despite Airbus withdrawing from a previous deal for a stake in Evidian in March, CEO Guillaume Faury remains open to a strategic partnership. Airbus's restructuring in 2024 aims to focus on defense and space, with Christian Scherer leading the planemaking division. Airbus delivered 64 aircraft in November, totaling 623 for the year. Airbus's subsidiary is also developing solar-powered drones for communication services. EADSY shares closed down 1.26% at $38.50.

Portfolio Pulse from Nabaparna Bhattacharya

December 15, 2023 | 1:17 pm

VRTX

Vertex Pharmaceuticals received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its drug CASGEVY, aimed at treating sickle cell disease and transfusion-dependent beta thalassemia. This is a significant step towards potential approval and commercialization in the European market.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 1:13 pm

MSFT

TSLA

Tesla CEO Elon Musk criticized Microsoft Word for flagging language it deems not 'inclusive', such as the word 'insane' used in the context of Cybertruck's stability. Musk, who has been a vocal opponent of 'wokeness', shared his frustration on X (formerly Twitter), highlighting the software's suggestions to describe the Cybertruck's towing capacity in unconventional terms.

Portfolio Pulse from Anan Ashraf

December 15, 2023 | 1:09 pm

MRNA

Moderna, Inc. (NASDAQ:MRNA) has published positive Phase 3 clinical trial results for its mRNA-1345 RSV vaccine in The New England Journal of Medicine. The study, ConquerRSV, shows the vaccine's safety and efficacy, marking a significant step in RSV vaccine development and mRNA technology. Moderna, the sole developer of an mRNA-based RSV vaccine, plans a 2024 launch for mRNA-1345, pending regulatory approval. The vaccine is expected to be best-in-class and the only ready-to-use RSV vaccine in single-dose prefilled syringes.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 1:05 pm

CBAY

CymaBay Therapeutics has announced the submission of a New Drug Application (NDA) to the FDA for Seladelpar, aimed at treating Primary Biliary Cholangitis (PBC). This step is crucial for the company as it seeks approval to market Seladelpar as a treatment option for PBC, a chronic liver disease. The FDA's acceptance of the NDA would be a significant milestone for CymaBay, potentially leading to future revenue streams from the drug if approved.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 1:01 pm